JP2005529925A - 乳癌および卵巣癌のアジュバント療法におけるドセタキセル/ドキソルビシン/シクロホスファミドの使用 - Google Patents
乳癌および卵巣癌のアジュバント療法におけるドセタキセル/ドキソルビシン/シクロホスファミドの使用 Download PDFInfo
- Publication number
- JP2005529925A JP2005529925A JP2004505157A JP2004505157A JP2005529925A JP 2005529925 A JP2005529925 A JP 2005529925A JP 2004505157 A JP2004505157 A JP 2004505157A JP 2004505157 A JP2004505157 A JP 2004505157A JP 2005529925 A JP2005529925 A JP 2005529925A
- Authority
- JP
- Japan
- Prior art keywords
- docetaxel
- doxorubicin
- cyclophosphamide
- patients
- adjuvant therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
Description
「アジュバンド療法」は、手術から60日以内であってそれより多くない時期に始めた化学療法を意味する。
「AT」は、アドリアマイシン/タキソテールを意味する;
「ドセタキセル」は、タキソテール(TAXOTERE)(R)の活性成分またはタキソテール(R)それ自体を意味する;
「ドキソルビシン」は、アドリアマイシン(ADRIAMYCIN)(R)の活性成分またはアドリアマイシン(R)それ自体を意味する;
「ER」はエストロゲン受容体を意味する。
「FAC」は、5−フルオロウラシル、ドキソルビシンおよびシクロホスファミドの組み合わせを意味する;
「HER2」は、上皮成長因子2受容体と部分的相同性を有する膜貫通型受容体チロシンキナーゼを意味し、それら両受容体は1型チロシンキナーゼ受容体スーパーファミリーに属する。
「KPS」は、患者の体の状態の指標である、Karnovsky活動度を意味する;
「MF」は、メトトレキセート/5−フルオロウラシルを意味する。
「MV」は、マイトマイシン/ビンブラスチンの組み合わせを意味する。
「PR」は、プロゲステロン受容体を意味する;
「TAC」は、タキソテール(C)(ドセタキセル)、アドリアマイシン(ドキソルビシン)およびシクロホスファミドの組み合わせを意味する;
そして
「薬剤」は、上記の活性成分またはそれらを含む医薬もしくは医薬調製物を意味する。
本発明の発明者は、臨床試験を介して、特にTAC製剤が新生物性疾患、特に乳癌、より特別にはER/PRおよびHER2が過剰発現している転移性乳癌の治療において、予想外の、そして強い治療効果を明らかにすることを検証した。一般的に本発明によれば、ドセタキセルは75mg/m2の投与量、ドキソルビシンは50mg/m2の投与量、そしてシクロホスファミドは500mg/m2の投与量で、3週間に一回投与される。このサイクルは、一般に6回繰り返される。
患者が組織学的に乳癌であり、腋窩のリンパ節切開(6つ以上のリンパ節)を伴う決定的な手術が行われ、手術と無作為化との間の期間が60日以下であり、ステージ1〜3の癌であり、少なくとも一つの結節が癌に関して陽性であると証明され、70歳以下であり、KPS指標が80%より大きいかまたは80%で、そして正常な骨髄、肝臓、腎臓および心機能を有する場合に、患者はその研究に対して適格であった。図4を参照。
デキサメタゾン、8mg BIDを3日間前治療として与えた。そして、併用アジュバ
ント療法を4日目に投与した。患者の1つの群は、ドセタキセル、ドキソルビシンおよびシクロホスファミド(TAC)がその順序で静注投与された。他の群の患者は、5−FU、ドキソルビシンおよびシクロホスファミド(FAQ)をその順序で静注投与された。そして、予防シプロ(prophylactic Cipro)を両群に5〜14日目に500mg BIDの用量で与えた。この薬物コースは、3週ごとに6サイクル繰り返された。図2を参照。
TACおよびFAC群の無疾患生存を結節の状態によって比較した場合、TACを受けた1〜3個の陽性結節を有する患者の90%は、治療の33ヵ月後、生存しており、無疾患だったのに対し、FAC群では79%であった。FACを受けた67%と比較して、TAC療法を受けた患者の69%は、36ヵ月で生存しており、無疾患だったが、4つの結節を有する患者における2つのアジュバント療法の間に統計的な差異はなかった。図15を参照。
ER/PR陰性腫瘍患者において、無疾患生存率は、TACアジュバンド療法を受けた患者では約70%であり、FACを受けた患者では約62%であった。ER/PR陽性結節を有する患者において、TACを受けた患者の無疾患生存率は、約88%であったのに対し、FACを受けた患者では約82%であった。図17および33を参照。
HER2陰性腫瘍患者において、33ヵ月における無疾患生存率は、TACアジュバンド療法を受けた患者では約86%であり、FACを受けた患者では約80%であった。HER2陽性腫瘍患者において、TACを受けた患者の無疾患生存率は約75%であったの
に対し、FACを受けた患者では60%であった。図19を参照。
Claims (11)
- アジュバンド療法が必要な患者に対し、アジュバンド療法として、ドセタキセル、ドキソルビシンおよびシクロホスファミドを投与することからなる、転移性乳癌または転移性卵巣癌を治療する方法。
- ドセタキセル、ドキソルビシンおよびシクロホスファミドが別々に投与される請求項1に記載の方法。
- 癌が転移性乳癌である、請求項1に記載の方法。
- 乳癌において、ER、PRおよび/またはHER2を過剰発現している請求項3に記載の方法。
- ドセタキセル、ドキソルビシンおよびシクロホスファミドの投与が、静脈経路を介するものである請求項2に記載の方法。
- ドセタキセル、ドキソルビシンおよびシクロホスファミドが3週間ごとに1回投与される請求項2に記載の方法。
- ドセタキセルが1サイクルあたり約75mg/m2の用量で投与される、請求項2に記載の方法。
- ドキソルビシンが1サイクルあたり約50mg/m2の用量で投与される、請求項6に記載の方法。
- シクロホスファミドが1サイクルあたり約500mg/m2の用量で投与される、請求項6に記載の方法。
- ドセタキセル、ドキソルビシンおよびシクロホスファミドからなるアジュバンド療法における使用のための治療医薬の組み合わせ。
- 約75mg/m2の用量のドセタキセル、約50mg/m2の用量のドキソルビシン、そして約500mg/m2の用量のシクロホスファミドを含む、請求項10に記載の治療医薬の組み合わせ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38085002P | 2002-05-17 | 2002-05-17 | |
US60/380,850 | 2002-05-17 | ||
PCT/EP2003/007443 WO2003097164A1 (en) | 2002-05-17 | 2003-05-15 | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005529925A true JP2005529925A (ja) | 2005-10-06 |
JP4773719B2 JP4773719B2 (ja) | 2011-09-14 |
Family
ID=29550025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004505157A Expired - Fee Related JP4773719B2 (ja) | 2002-05-17 | 2003-05-15 | 乳癌および卵巣癌のアジュバント療法におけるドセタキセル/ドキソルビシン/シクロホスファミドの使用 |
Country Status (28)
Country | Link |
---|---|
US (2) | US20040014694A1 (ja) |
EP (1) | EP1507573A1 (ja) |
JP (1) | JP4773719B2 (ja) |
KR (1) | KR20050000544A (ja) |
CN (1) | CN1652845A (ja) |
AU (1) | AU2003244646B2 (ja) |
BR (1) | BR0310026A (ja) |
CA (1) | CA2486124A1 (ja) |
CR (1) | CR7575A (ja) |
EC (1) | ECSP045433A (ja) |
HR (1) | HRPK20041072B3 (ja) |
IL (1) | IL165214A0 (ja) |
MA (1) | MA27417A1 (ja) |
ME (2) | MEP16308A (ja) |
MX (1) | MXPA04010640A (ja) |
MY (1) | MY146533A (ja) |
NO (1) | NO20045370L (ja) |
NZ (1) | NZ535992A (ja) |
OA (1) | OA12819A (ja) |
PA (1) | PA8574001A1 (ja) |
RS (1) | RS96304A (ja) |
RU (1) | RU2321396C2 (ja) |
TN (1) | TNSN04217A1 (ja) |
TW (1) | TWI374741B (ja) |
UA (1) | UA81628C2 (ja) |
UY (1) | UY27812A1 (ja) |
WO (1) | WO2003097164A1 (ja) |
ZA (1) | ZA200408549B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007511498A (ja) * | 2003-11-14 | 2007-05-10 | ファーマ・マール・エス・アー・ウー | Et−743とドキソルビシンとを使用することを含むガンの併用療法 |
JP2014509639A (ja) * | 2011-04-01 | 2014-04-21 | アストラゼネカ アクチボラグ | 療法的治療 |
JP2020514412A (ja) * | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06003222A (es) * | 2003-09-25 | 2006-05-22 | Astellas Pharma Inc | Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii. |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US20080085879A1 (en) * | 2006-08-31 | 2008-04-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation |
WO2013079964A1 (en) | 2011-11-30 | 2013-06-06 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
KR20160141857A (ko) * | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
WO2017068227A1 (es) * | 2015-10-22 | 2017-04-27 | Universidade De Santiago De Compostela | Métodos para utilizar reguladores de aumento de la expresión o activación de p53 y/o reguladores de disminución o inhibidores de la expresión de p63-alfa para el tratamiento de nafld (enfermedad de hígado graso no-alcohólico) y/o nash (esteatohepatitis no- alcohólica) |
US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
WO2018039452A1 (en) * | 2016-08-24 | 2018-03-01 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers with chemotherapy with reduced toxicity |
WO2018067575A1 (en) * | 2016-10-03 | 2018-04-12 | Indiana University Research And Technology Corporation | Combination drug therapy reduces parp-1 related dna repair and increases the efficacy of genotoxic agents |
EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
HUE064898T2 (hu) | 2017-03-02 | 2024-04-28 | Genentech Inc | HER2-pozitív emlõrák adjuváns kezelése |
WO2019147615A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
KR20210048483A (ko) * | 2018-06-22 | 2021-05-03 | 오하이오 스테이트 이노베이션 파운데이션 | 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
US6262054B1 (en) * | 1996-02-01 | 2001-07-17 | Sloan-Kettering Institute Of Cancer Research | Combination therapy method for treating breast cancer using edatrexate |
US6323205B1 (en) * | 1996-07-17 | 2001-11-27 | Sloan-Kettering Institute For Cancer Research | Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors |
US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
-
2003
- 2003-05-15 KR KR10-2004-7018431A patent/KR20050000544A/ko not_active Application Discontinuation
- 2003-05-15 MX MXPA04010640A patent/MXPA04010640A/es active IP Right Grant
- 2003-05-15 CA CA002486124A patent/CA2486124A1/en not_active Abandoned
- 2003-05-15 IL IL16521403A patent/IL165214A0/xx unknown
- 2003-05-15 EP EP03738122A patent/EP1507573A1/en not_active Withdrawn
- 2003-05-15 RU RU2004136984/15A patent/RU2321396C2/ru not_active IP Right Cessation
- 2003-05-15 ME MEP-163/08A patent/MEP16308A/xx unknown
- 2003-05-15 RS YU96304A patent/RS96304A/sr unknown
- 2003-05-15 JP JP2004505157A patent/JP4773719B2/ja not_active Expired - Fee Related
- 2003-05-15 UA UA20041210381A patent/UA81628C2/uk unknown
- 2003-05-15 CN CNA038112388A patent/CN1652845A/zh active Pending
- 2003-05-15 BR BR0310026-0A patent/BR0310026A/pt not_active IP Right Cessation
- 2003-05-15 OA OA1200400307A patent/OA12819A/en unknown
- 2003-05-15 ME MEP-2008-163A patent/ME00055B/me unknown
- 2003-05-15 NZ NZ535992A patent/NZ535992A/en not_active IP Right Cessation
- 2003-05-15 WO PCT/EP2003/007443 patent/WO2003097164A1/en active Application Filing
- 2003-05-15 AU AU2003244646A patent/AU2003244646B2/en not_active Ceased
- 2003-05-16 UY UY27812A patent/UY27812A1/es not_active Application Discontinuation
- 2003-05-16 PA PA20038574001A patent/PA8574001A1/es unknown
- 2003-05-16 US US10/439,827 patent/US20040014694A1/en not_active Abandoned
- 2003-05-16 TW TW092113275A patent/TWI374741B/zh not_active IP Right Cessation
- 2003-05-16 MY MYPI20031829A patent/MY146533A/en unknown
-
2004
- 2004-10-21 ZA ZA2004/08549A patent/ZA200408549B/en unknown
- 2004-11-03 MA MA27924A patent/MA27417A1/fr unknown
- 2004-11-11 TN TNP2004000217A patent/TNSN04217A1/en unknown
- 2004-11-16 EC EC2004005433A patent/ECSP045433A/es unknown
- 2004-11-16 HR HR20041072A patent/HRPK20041072B3/xx not_active IP Right Cessation
- 2004-11-17 CR CR7575A patent/CR7575A/es unknown
- 2004-12-08 NO NO20045370A patent/NO20045370L/no not_active Application Discontinuation
-
2007
- 2007-06-28 US US11/769,859 patent/US20070265213A1/en not_active Abandoned
Non-Patent Citations (10)
Title |
---|
JPN5004016466, IKEDA T, EUROPEAN JOURNAL OF CANCER, 200009, Vol.36, Suppl.5, S78 * |
JPN5004016467, MAMOUNAS E P, ONCOLOGY, 199706, Vol.11, No.6, Suppl.6, pp.37−40, US * |
JPN5004016468, CLINICAL BREAST CANCER, 2002, Vol.3, No.1, pp.26−28, US * |
JPN5004016469, DI LEO A, ANNALS OF ONCOLOGY : OFFICIAL JOURNAL OF THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY / ESMO, 200002, Vol.11, No.2, pp.169−175, NL * |
JPN5004016470, D’ORAZIO A I, CLINICAL BREAST CANCER, 2002, Vol.3, No.2, pp.103−105, US * |
JPN5004016471, ANTON A, "SEQUENTIAL TREATMENT OF DOCETAXEL PLUS DOXORUBICIN/CYCLOPHOSPHAMIDE (AC) AS FIRST−LINE", EUROPEAN JOURNAL OF CANCER, 200203, Vol.38, S68−69, GB, PERGAMON PRESS * |
JPN5004016472, NABHOLTZ JEAN−MARC, SEMINARS IN ONCOLOGY, 199810, Vol.25, No.5, Suppl.12, pp.27−31 * |
JPN5004016473, NABHOLTZ JEAN−MARC, SEMINARS IN ONCOLOGY, 199906, Vol.26, No.3, Suppl.8, pp.47−52 * |
JPN5004016474, NABHOLTZ JEAN−MARC, SEMINARS IN ONCOLOGY, 199902, Vol.26, No.1, Suppl.3, pp.10−16 * |
JPN5004016475, NABHOLTZ JEAN−MARC, ONCOLOGY, 199708, Vol.11, No.8, Suppl.8, pp.48−52, US * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007511498A (ja) * | 2003-11-14 | 2007-05-10 | ファーマ・マール・エス・アー・ウー | Et−743とドキソルビシンとを使用することを含むガンの併用療法 |
JP2014509639A (ja) * | 2011-04-01 | 2014-04-21 | アストラゼネカ アクチボラグ | 療法的治療 |
JP2020514412A (ja) * | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
Also Published As
Publication number | Publication date |
---|---|
NZ535992A (en) | 2008-11-28 |
MA27417A1 (fr) | 2005-07-01 |
MY146533A (en) | 2012-08-15 |
MEP16308A (en) | 2010-06-10 |
US20070265213A1 (en) | 2007-11-15 |
US20040014694A1 (en) | 2004-01-22 |
HRPK20041072B3 (en) | 2007-07-31 |
CN1652845A (zh) | 2005-08-10 |
OA12819A (en) | 2006-07-10 |
PA8574001A1 (es) | 2003-12-19 |
MXPA04010640A (es) | 2005-08-16 |
EP1507573A1 (en) | 2005-02-23 |
TWI374741B (en) | 2012-10-21 |
TNSN04217A1 (en) | 2007-03-12 |
ECSP045433A (es) | 2005-01-03 |
UA81628C2 (uk) | 2008-01-25 |
CR7575A (es) | 2006-05-10 |
TW200407152A (en) | 2004-05-16 |
UY27812A1 (es) | 2003-11-28 |
NO20045370L (no) | 2004-12-08 |
KR20050000544A (ko) | 2005-01-05 |
JP4773719B2 (ja) | 2011-09-14 |
IL165214A0 (en) | 2005-12-18 |
RU2004136984A (ru) | 2005-06-27 |
WO2003097164A1 (en) | 2003-11-27 |
ME00055B (me) | 2010-10-10 |
AU2003244646B2 (en) | 2008-08-07 |
HRP20041072A2 (en) | 2005-06-30 |
RS96304A (en) | 2006-10-27 |
AU2003244646A1 (en) | 2003-12-02 |
RU2321396C2 (ru) | 2008-04-10 |
ZA200408549B (en) | 2006-01-25 |
BR0310026A (pt) | 2005-02-15 |
CA2486124A1 (en) | 2003-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4773719B2 (ja) | 乳癌および卵巣癌のアジュバント療法におけるドセタキセル/ドキソルビシン/シクロホスファミドの使用 | |
Choy et al. | A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study) | |
Yeo et al. | A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma | |
Fennelly et al. | Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. | |
EP2127652A1 (en) | Method for treating cancer using anticancer agent in combination | |
Adachi et al. | A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer | |
EP1796688B1 (en) | Pancreatic cancer treatment using na+/k+ atpase inhibitors | |
Arbuck et al. | Paclitaxel (Taxol) in breast cancer | |
Pectasides et al. | Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study | |
Petrioli et al. | Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel | |
AU718041B2 (en) | Combination therapy method for treating cancer using edatrexate and a taxane derivative, e.g. Paclitaxel | |
Kim et al. | Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer | |
Valero | Managing ixabepilone adverse events with dose reduction | |
Michels et al. | A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer | |
Kubota et al. | Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer | |
WO2004103355A1 (en) | Method for augmenting the antitumor activity of anti-cancer agents | |
Sun et al. | Multi-center phase II trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer | |
Katori et al. | Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) | |
Zimatore et al. | Weekly taxanes in metastatic breast cancer | |
Karavasilis et al. | Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy | |
Milano et al. | Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck | |
Seki et al. | Feasibility study of nanoparticle albumin-bound-paclitaxel and S-1 followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with operable breast cancer: A prospective study | |
JPH10511108A (ja) | テモゾロミドおよびシスプラチンを含む進行ガンに対する組み合わせ治療 | |
Davis et al. | Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer | |
Mougenot et al. | In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091020 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100119 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100709 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101102 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110131 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110207 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110531 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110624 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140701 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |